Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-12-03

FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) from Gilead Sciences, Inc., resulting in a label change to reflect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Descovy (emtricitabine/tenofovir alafenamide)

Snippet

SUPPL AP for DESCOVY (EMTRICITABINE AND TENOFOVIR ALAFENAMIDE)